Amgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not ... - StreetInsider.com

Channel NewsAsia

Amgen (AMGN), Allergan (AGN) Announce Results from ABP 980 Phase 3 in HER2+ Breast Cancer; Superiority Not ... StreetInsider.com News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. Amgen (Nasdaq: AMGN) and Allergan plc (NYSE: AGN) announced results from a Phase 3 study evaluating efficacy and safety of ... Amgen, Allergan biosimilar found as effective as Roche cancer drugReuters Late-stage study shows biosimilar candidate ABP 980 non-inferior to Roche's HerceptinSeeking Alpha Shares now up at $163.39 (AMGN) Amgen And Allergan Announce Top-Line...Finance Daily all 5 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNG4PywwFc8k3EpO5xC7W9ivfFwdsg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779164846615&ei=RuSQV5CPFZSL3AGV0ZHoAg&url=http://www.streetinsider.com/Corporate%2BNews/Amgen%2B(AMGN),%2BAllergan%2B(AGN)%2BAnnounce%2BResults%2Bfrom%2BABP%2B980%2BPhase%2B3%2Bin%2BHER2%252B%2BBreast%2BCancer%253B%2BSuperiority%2BNot%2BRuled%2BOut/11850305.html
via IFTTT